Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treat...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2020-06, Vol.25 (6), p.e993-e997 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e997 |
|---|---|
| container_issue | 6 |
| container_start_page | e993 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 25 |
| creator | Merryman, Reid W. Carreau, Nicole A. Advani, Ranjana H. Spinner, Michael A. Herrera, Alex F. Chen, Robert Tomassetti, Sarah Ramchandren, Radhakrishnan Hamid, Muhammad Assouline, Sarit Santiago, Raoul Wagner‐Johnston, Nina Paul, Suman Svoboda, Jakub Bair, Steven M. Barta, Stefan K. Liu, Yang Nathan, Sunita Karmali, Reem Burkart, Madelyn Torka, Pallawi David, Kevin A. Wei, Catherine Lansigan, Frederick Emery, Lukas Persky, Daniel Smith, Sonali M. Godfrey, James Chavez, Julio Cohen, Jonathan B. Troxel, Andrea B. Diefenbach, Catherine Armand, Philippe |
| description | Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non‐TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression‐free survival with post‐ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time‐to‐subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.
To investigate the potential benefit of treatment beyond progression in patients with Hodgkin lymphoma, a multicenter retrospective analysis of 64 patients treated with immune checkpoint blockade was performed. Some patients stopped therapy at initial progression and some received treatment beyond progression. Results are reported here. |
| doi_str_mv | 10.1634/theoncologist.2020-0040 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7288660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2388825798</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4727-60120f19d4946f972294055f65d84a516ccfb66a342496bd383eeb87310ca2fb3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0EoqXwF8BHLin-ij8uSLACutKK5VAkxMVynMnGbBwHO0u1_56sWgq9cZpXmnfemdGD0CtKLqnk4s3cQxp9GtIulPmSEUYqQgR5hM5pLUwlDPn2eNFE80rR2pyhZ6X8IGSRnD1FZ5wxVSstz9H3dZycn3Hq8HUGN0cYZ_wejmls8ZecdhlKCWnEN2Hu8TrGwwh41YPfTymcnEPye9cCDiO-Su1uv9TNMU59iu45etK5ocCLu3qBvn78cL26qjbbT-vVu03lhWKqkoQy0lHTCiNkZxRjRpC67mTdauFqKr3vGikdF0wY2bRcc4BGK06Jd6xr-AV6e5s7HZoIrV8-yG6wUw7R5aNNLtiHnTH0dpd-WcW0lpIsAa_vAnL6eYAy2xiKh2FwI6RDsYxrrVmtjF6s6tbqcyolQ3e_hhJ7ImMfkLEnMvZEZpl8-e-V93N_UPx94yYMcPzfXLv9vNpSzqnivwH5yaQZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2388825798</pqid></control><display><type>article</type><title>Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma</title><source>Oxford Journals Open Access Collection</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Merryman, Reid W. ; Carreau, Nicole A. ; Advani, Ranjana H. ; Spinner, Michael A. ; Herrera, Alex F. ; Chen, Robert ; Tomassetti, Sarah ; Ramchandren, Radhakrishnan ; Hamid, Muhammad ; Assouline, Sarit ; Santiago, Raoul ; Wagner‐Johnston, Nina ; Paul, Suman ; Svoboda, Jakub ; Bair, Steven M. ; Barta, Stefan K. ; Liu, Yang ; Nathan, Sunita ; Karmali, Reem ; Burkart, Madelyn ; Torka, Pallawi ; David, Kevin A. ; Wei, Catherine ; Lansigan, Frederick ; Emery, Lukas ; Persky, Daniel ; Smith, Sonali M. ; Godfrey, James ; Chavez, Julio ; Cohen, Jonathan B. ; Troxel, Andrea B. ; Diefenbach, Catherine ; Armand, Philippe</creator><creatorcontrib>Merryman, Reid W. ; Carreau, Nicole A. ; Advani, Ranjana H. ; Spinner, Michael A. ; Herrera, Alex F. ; Chen, Robert ; Tomassetti, Sarah ; Ramchandren, Radhakrishnan ; Hamid, Muhammad ; Assouline, Sarit ; Santiago, Raoul ; Wagner‐Johnston, Nina ; Paul, Suman ; Svoboda, Jakub ; Bair, Steven M. ; Barta, Stefan K. ; Liu, Yang ; Nathan, Sunita ; Karmali, Reem ; Burkart, Madelyn ; Torka, Pallawi ; David, Kevin A. ; Wei, Catherine ; Lansigan, Frederick ; Emery, Lukas ; Persky, Daniel ; Smith, Sonali M. ; Godfrey, James ; Chavez, Julio ; Cohen, Jonathan B. ; Troxel, Andrea B. ; Diefenbach, Catherine ; Armand, Philippe</creatorcontrib><description>Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non‐TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression‐free survival with post‐ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time‐to‐subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.
To investigate the potential benefit of treatment beyond progression in patients with Hodgkin lymphoma, a multicenter retrospective analysis of 64 patients treated with immune checkpoint blockade was performed. Some patients stopped therapy at initial progression and some received treatment beyond progression. Results are reported here.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1634/theoncologist.2020-0040</identifier><identifier>PMID: 32275786</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Brief Communications</subject><ispartof>The oncologist (Dayton, Ohio), 2020-06, Vol.25 (6), p.e993-e997</ispartof><rights>AlphaMed Press 2020</rights><rights>AlphaMed Press 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4727-60120f19d4946f972294055f65d84a516ccfb66a342496bd383eeb87310ca2fb3</citedby><cites>FETCH-LOGICAL-c4727-60120f19d4946f972294055f65d84a516ccfb66a342496bd383eeb87310ca2fb3</cites><orcidid>0000-0002-6360-3234</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288660/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288660/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,27901,27902,45550,45551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32275786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Merryman, Reid W.</creatorcontrib><creatorcontrib>Carreau, Nicole A.</creatorcontrib><creatorcontrib>Advani, Ranjana H.</creatorcontrib><creatorcontrib>Spinner, Michael A.</creatorcontrib><creatorcontrib>Herrera, Alex F.</creatorcontrib><creatorcontrib>Chen, Robert</creatorcontrib><creatorcontrib>Tomassetti, Sarah</creatorcontrib><creatorcontrib>Ramchandren, Radhakrishnan</creatorcontrib><creatorcontrib>Hamid, Muhammad</creatorcontrib><creatorcontrib>Assouline, Sarit</creatorcontrib><creatorcontrib>Santiago, Raoul</creatorcontrib><creatorcontrib>Wagner‐Johnston, Nina</creatorcontrib><creatorcontrib>Paul, Suman</creatorcontrib><creatorcontrib>Svoboda, Jakub</creatorcontrib><creatorcontrib>Bair, Steven M.</creatorcontrib><creatorcontrib>Barta, Stefan K.</creatorcontrib><creatorcontrib>Liu, Yang</creatorcontrib><creatorcontrib>Nathan, Sunita</creatorcontrib><creatorcontrib>Karmali, Reem</creatorcontrib><creatorcontrib>Burkart, Madelyn</creatorcontrib><creatorcontrib>Torka, Pallawi</creatorcontrib><creatorcontrib>David, Kevin A.</creatorcontrib><creatorcontrib>Wei, Catherine</creatorcontrib><creatorcontrib>Lansigan, Frederick</creatorcontrib><creatorcontrib>Emery, Lukas</creatorcontrib><creatorcontrib>Persky, Daniel</creatorcontrib><creatorcontrib>Smith, Sonali M.</creatorcontrib><creatorcontrib>Godfrey, James</creatorcontrib><creatorcontrib>Chavez, Julio</creatorcontrib><creatorcontrib>Cohen, Jonathan B.</creatorcontrib><creatorcontrib>Troxel, Andrea B.</creatorcontrib><creatorcontrib>Diefenbach, Catherine</creatorcontrib><creatorcontrib>Armand, Philippe</creatorcontrib><title>Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non‐TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression‐free survival with post‐ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time‐to‐subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.
To investigate the potential benefit of treatment beyond progression in patients with Hodgkin lymphoma, a multicenter retrospective analysis of 64 patients treated with immune checkpoint blockade was performed. Some patients stopped therapy at initial progression and some received treatment beyond progression. Results are reported here.</description><subject>Brief Communications</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkU1v1DAQhi0EoqXwF8BHLin-ij8uSLACutKK5VAkxMVynMnGbBwHO0u1_56sWgq9cZpXmnfemdGD0CtKLqnk4s3cQxp9GtIulPmSEUYqQgR5hM5pLUwlDPn2eNFE80rR2pyhZ6X8IGSRnD1FZ5wxVSstz9H3dZycn3Hq8HUGN0cYZ_wejmls8ZecdhlKCWnEN2Hu8TrGwwh41YPfTymcnEPye9cCDiO-Su1uv9TNMU59iu45etK5ocCLu3qBvn78cL26qjbbT-vVu03lhWKqkoQy0lHTCiNkZxRjRpC67mTdauFqKr3vGikdF0wY2bRcc4BGK06Jd6xr-AV6e5s7HZoIrV8-yG6wUw7R5aNNLtiHnTH0dpd-WcW0lpIsAa_vAnL6eYAy2xiKh2FwI6RDsYxrrVmtjF6s6tbqcyolQ3e_hhJ7ImMfkLEnMvZEZpl8-e-V93N_UPx94yYMcPzfXLv9vNpSzqnivwH5yaQZ</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Merryman, Reid W.</creator><creator>Carreau, Nicole A.</creator><creator>Advani, Ranjana H.</creator><creator>Spinner, Michael A.</creator><creator>Herrera, Alex F.</creator><creator>Chen, Robert</creator><creator>Tomassetti, Sarah</creator><creator>Ramchandren, Radhakrishnan</creator><creator>Hamid, Muhammad</creator><creator>Assouline, Sarit</creator><creator>Santiago, Raoul</creator><creator>Wagner‐Johnston, Nina</creator><creator>Paul, Suman</creator><creator>Svoboda, Jakub</creator><creator>Bair, Steven M.</creator><creator>Barta, Stefan K.</creator><creator>Liu, Yang</creator><creator>Nathan, Sunita</creator><creator>Karmali, Reem</creator><creator>Burkart, Madelyn</creator><creator>Torka, Pallawi</creator><creator>David, Kevin A.</creator><creator>Wei, Catherine</creator><creator>Lansigan, Frederick</creator><creator>Emery, Lukas</creator><creator>Persky, Daniel</creator><creator>Smith, Sonali M.</creator><creator>Godfrey, James</creator><creator>Chavez, Julio</creator><creator>Cohen, Jonathan B.</creator><creator>Troxel, Andrea B.</creator><creator>Diefenbach, Catherine</creator><creator>Armand, Philippe</creator><general>John Wiley & Sons, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6360-3234</orcidid></search><sort><creationdate>202006</creationdate><title>Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma</title><author>Merryman, Reid W. ; Carreau, Nicole A. ; Advani, Ranjana H. ; Spinner, Michael A. ; Herrera, Alex F. ; Chen, Robert ; Tomassetti, Sarah ; Ramchandren, Radhakrishnan ; Hamid, Muhammad ; Assouline, Sarit ; Santiago, Raoul ; Wagner‐Johnston, Nina ; Paul, Suman ; Svoboda, Jakub ; Bair, Steven M. ; Barta, Stefan K. ; Liu, Yang ; Nathan, Sunita ; Karmali, Reem ; Burkart, Madelyn ; Torka, Pallawi ; David, Kevin A. ; Wei, Catherine ; Lansigan, Frederick ; Emery, Lukas ; Persky, Daniel ; Smith, Sonali M. ; Godfrey, James ; Chavez, Julio ; Cohen, Jonathan B. ; Troxel, Andrea B. ; Diefenbach, Catherine ; Armand, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4727-60120f19d4946f972294055f65d84a516ccfb66a342496bd383eeb87310ca2fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Brief Communications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Merryman, Reid W.</creatorcontrib><creatorcontrib>Carreau, Nicole A.</creatorcontrib><creatorcontrib>Advani, Ranjana H.</creatorcontrib><creatorcontrib>Spinner, Michael A.</creatorcontrib><creatorcontrib>Herrera, Alex F.</creatorcontrib><creatorcontrib>Chen, Robert</creatorcontrib><creatorcontrib>Tomassetti, Sarah</creatorcontrib><creatorcontrib>Ramchandren, Radhakrishnan</creatorcontrib><creatorcontrib>Hamid, Muhammad</creatorcontrib><creatorcontrib>Assouline, Sarit</creatorcontrib><creatorcontrib>Santiago, Raoul</creatorcontrib><creatorcontrib>Wagner‐Johnston, Nina</creatorcontrib><creatorcontrib>Paul, Suman</creatorcontrib><creatorcontrib>Svoboda, Jakub</creatorcontrib><creatorcontrib>Bair, Steven M.</creatorcontrib><creatorcontrib>Barta, Stefan K.</creatorcontrib><creatorcontrib>Liu, Yang</creatorcontrib><creatorcontrib>Nathan, Sunita</creatorcontrib><creatorcontrib>Karmali, Reem</creatorcontrib><creatorcontrib>Burkart, Madelyn</creatorcontrib><creatorcontrib>Torka, Pallawi</creatorcontrib><creatorcontrib>David, Kevin A.</creatorcontrib><creatorcontrib>Wei, Catherine</creatorcontrib><creatorcontrib>Lansigan, Frederick</creatorcontrib><creatorcontrib>Emery, Lukas</creatorcontrib><creatorcontrib>Persky, Daniel</creatorcontrib><creatorcontrib>Smith, Sonali M.</creatorcontrib><creatorcontrib>Godfrey, James</creatorcontrib><creatorcontrib>Chavez, Julio</creatorcontrib><creatorcontrib>Cohen, Jonathan B.</creatorcontrib><creatorcontrib>Troxel, Andrea B.</creatorcontrib><creatorcontrib>Diefenbach, Catherine</creatorcontrib><creatorcontrib>Armand, Philippe</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Merryman, Reid W.</au><au>Carreau, Nicole A.</au><au>Advani, Ranjana H.</au><au>Spinner, Michael A.</au><au>Herrera, Alex F.</au><au>Chen, Robert</au><au>Tomassetti, Sarah</au><au>Ramchandren, Radhakrishnan</au><au>Hamid, Muhammad</au><au>Assouline, Sarit</au><au>Santiago, Raoul</au><au>Wagner‐Johnston, Nina</au><au>Paul, Suman</au><au>Svoboda, Jakub</au><au>Bair, Steven M.</au><au>Barta, Stefan K.</au><au>Liu, Yang</au><au>Nathan, Sunita</au><au>Karmali, Reem</au><au>Burkart, Madelyn</au><au>Torka, Pallawi</au><au>David, Kevin A.</au><au>Wei, Catherine</au><au>Lansigan, Frederick</au><au>Emery, Lukas</au><au>Persky, Daniel</au><au>Smith, Sonali M.</au><au>Godfrey, James</au><au>Chavez, Julio</au><au>Cohen, Jonathan B.</au><au>Troxel, Andrea B.</au><au>Diefenbach, Catherine</au><au>Armand, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2020-06</date><risdate>2020</risdate><volume>25</volume><issue>6</issue><spage>e993</spage><epage>e997</epage><pages>e993-e997</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non‐TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression‐free survival with post‐ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time‐to‐subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.
To investigate the potential benefit of treatment beyond progression in patients with Hodgkin lymphoma, a multicenter retrospective analysis of 64 patients treated with immune checkpoint blockade was performed. Some patients stopped therapy at initial progression and some received treatment beyond progression. Results are reported here.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>32275786</pmid><doi>10.1634/theoncologist.2020-0040</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-6360-3234</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2020-06, Vol.25 (6), p.e993-e997 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7288660 |
| source | Oxford Journals Open Access Collection; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Brief Communications |
| title | Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T04%3A26%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Treatment%20Beyond%20Progression%20with%20Immune%20Checkpoint%20Blockade%20in%20Hodgkin%20Lymphoma&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Merryman,%20Reid%20W.&rft.date=2020-06&rft.volume=25&rft.issue=6&rft.spage=e993&rft.epage=e997&rft.pages=e993-e997&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1634/theoncologist.2020-0040&rft_dat=%3Cproquest_pubme%3E2388825798%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2388825798&rft_id=info:pmid/32275786&rfr_iscdi=true |